摘要: Reports that US President Bill Clinton vetoed an item that would have allowed New York State to continue taxing healthcare providers in the state. State government's criticism of the veto; Plans of pursuing the overturn of the veto; Benefits to managed care providers in the state....
Thus, routine use of the test may lead to inequitable access to the healthcare. Overall, the Guideline Development Group (GDG) concluded that the benefits of using AST to guide the therapy can outweigh the potential adverse effects and that its use should be encouraged at least in people on...
feels and behaves. 5 It is estimated to impact approximately 2.8 million people in the United States. 6 Symptoms typically first appear in early adulthood and present differently in each person, making symptoms difficult to diagnose and manage. 6 While the current standard of care can be ...
Professor Jun GUO from Beijing Cancer Hospital, said, “Within the last 5 years, toripalimab has become the standard therapy for second-line and beyond salvage treatment of advanced melanoma in China, which significantly altered the treatment landscape and offered groundbreaking survival benefits to m...
Sugemalimab remains the first and only anti-PD-L1 monoclonal antibody to present long-term survival benefits when combined with platinum-based chemotherapy as a first-line treatment for both squamous and non-squamous non-small cell lung cancer (NSCLC). ...
This website is intended only for use by US healthcare professionals. If you are a patient or a caregiver, please visit the Patient & Caregivers website.Home Congresses All our specialtiesCardiovascular 2024 ESC 2024 ESH 2024 Archives Dermatology ...
as a standard of care, and long-term and real-world data such as these presented at ASCO GU 2023, continue adding to the evidence supporting its benefits for patients with advanced bladder cancer,” said Tamas Sütö, MD, PhD, Senior Vice President & Head of Medical Unit Oncology, Merck...
Merck and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA with respective clinical criteria and conditions for adult patients with advanced (not amenable to curativ...
management’s expectations, beliefs and intentions regarding, among other things, the potential benefits of APHEXDA, the timing and execution of the launch of APHEXDA and the plans and objectives of management for future ope...
Tislelizumab combined with chemotherapy has shown significant clinical benefits in improving overall survival compared to chemotherapy alone for patients with extensive-stage small-cell lung cancer (ES-SCLC).#This study aimed to evaluate the cost-effectiveness of tislelizumab plus chemotherapy versus ...